PHARMA SERVICES

Biomarker & Companion Diagnostic Discovery
with Genomic Intelligence®

A COST-EFFECTIVE, HIGH-VALUE INSURANCE POLICY FOR EXPENSIVE CLINICAL TRIALS

Lack of efficacy or adverse effects are the leading cause of clinical trial failure. Mining data from such trials can identify predictive genomic biomarkers that stratify the subset of patients for whom the drug is effective and safe, giving new life to the molecule.

But if you haven’t laid a foundation for such analyses at the start of the trial, it will be too late to collect the necessary samples and data once efficacy or safety issues are experienced. Partner with Variantyx before your clinical trial starts to insure against unnecessary loss of valuable data and time.

OUR FOUR STEP PROCESS

UNPARALLELED BIOMARKER ANALYSIS CAPABILITIES

Proprietary method and technology powered by unique data

Our WGS-based testing methodology utilizes proprietary algorithms to detect all major types of genetic variation, identifying a comprehensive set of potential biomarkers. We are able to stratify trial participants according to unique data points available only within our data collection, including:

  • Curated clinically relevant tandem repeat expansions
  • Curated previously “unmapped” structural variants 2+ billion variants and their population frequencies (including frequencies of CNVs and repeat expansions)
  • Knowledgebase of tens of thousands of previously analyzed variants
  • Medical records of thousands of patients

This combination of method, technology and data enables better biomarker discovery and companion diagnostic development that may save the molecule and provide a new path to FDA approval.

AN ONCOLOGY BIOPHARMA PARTNER CASE STUDY

We are currently working with a well-known oncology biopharma partner to stratify patients due to differential adverse effects experienced during a recent phase II trial. A subset of the 500 biobanked patient samples were divided into two cohorts of 25 – one cohort having experienced adverse effects and the other not. Following whole genome sequencing, the cohorts were analyzed for potential genetic biomarkers. Promising initial findings are currently being investigated through sequencing and analysis of additional biobanked samples.

Please do not submit Protected Health Information (PHI) through this email address.

If you need to submit Protected Health Information (PHI), please call us at 617-209-2090 and we will work with you to submit the information through an alternate mechanism.

Otherwise, please continue: